NCT02785068View on ClinicalTrials.gov

Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

October 31, 2018

Conditions
Colorectal Cancer
Interventions
DRUG

MM-151

Oligoclonal antibody

DRUG

nal-IRI

Nanoliposomal irinotecan

DRUG

Leucovorin

folinic acid

DRUG

5-FU

Chemotherapy

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT02785068 - Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter